Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats

Cevimeline-induced anti-inflammatory effect through upregulations of mucins in the ocular surface of a dry eye mouse model

(2021) Chae Eun Kim et al.   BIOMEDICINE & PHARMACOTHERAPY

The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats

(2020) Jiamei Lian et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders

(2020) Yueqing Su et al.   PHARMACOLOGICAL RESEARCH

Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway

(2019) Xue-mei Liu et al.   ACTA PHARMACOLOGICA SINICA

Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex

(2019) Keisuke Obara et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Are There Gender Differences in the Response to Antipsychotic Drugs?

(2019) Mary V. Seeman   NEUROPHARMACOLOGY

Muscarinic receptors in energy homeostasis: Physiology and pharmacology

(2019) Sarah Falk et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKKβ/AMPK pathway

(2019) Ravirajsinh N. Jadeja et al.   BIOCHEMICAL PHARMACOLOGY

Liver kinase B1/AMP-activated protein kinase-mediated regulation by gentiopicroside ameliorates P2X7 receptor-dependent alcoholic hepatosteatosis

(2018) Xia Li et al.   BRITISH JOURNAL OF PHARMACOLOGY

Obesity exacerbates the acute metabolic side effects of olanzapine

(2018) Logan K. Townsend et al.   PSYCHONEUROENDOCRINOLOGY

Management of common adverse effects of antipsychotic medications

(2018) T. Scott Stroup et al.   World Psychiatry

Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha

(2018) Liying Ren et al.   JOURNAL OF ETHNOPHARMACOLOGY

AMPK as a Therapeutic Target for Treating Metabolic Diseases

(2017) Emily A. Day et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes

(2017) Jiezhong Chen et al.   Frontiers in Neuroscience

Treatment of nonalcoholic fatty liver disease: role of AMPK

(2016) Brennan K. Smith et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Hepatic glucose and lipid metabolism

(2016) John G. Jones   DIABETOLOGIA

Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology

(2016) David J Nutt et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

(2016) Jiamei Lian et al.   PHARMACOLOGICAL RESEARCH

Acetylcholine ameliorates endoplasmic reticulum stress in endothelial cells after hypoxia/reoxygenation via M3 AChR-AMPK signaling

(2015) Xueyuan Bi et al.   CELL CYCLE

Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain

(2015) J. Fernø et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Translating dosages from animal models to human clinical trials—revisiting body surface area scaling

(2015) Otis L. Blanchard et al.   FASEB JOURNAL

Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats

(2015) Xuemei Liu et al.   LIFE SCIENCES

Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways

(2015) Xuemei Liu et al.   PHARMACOLOGICAL RESEARCH

Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology

(2015) Leonel E. Rojo et al.   PHARMACOLOGICAL RESEARCH

Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis

(2015) Davy Vancampfort et al.   World Psychiatry

Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment

(2014) Jiamei Lian et al.   PLoS One

Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways

(2014) Jiamei Lian et al.   PSYCHONEUROENDOCRINOLOGY

Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor

(2013) Katrina Weston-Green et al.   CNS DRUGS

Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance

(2013) Chao Deng   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Modelling olanzapine-induced weight gain in rats

(2013) E. M. van der Zwaal et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Vagus Nerve Stimulation Reduces Body Weight and Fat Mass in Rats

(2012) Sebastiano Banni et al.   PLoS One

Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism

(2011) Kyoung-Jin Oh et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Activated AMPK inhibits PPAR-α and PPAR-γ transcriptional activity in hepatoma cells

(2011) Margaret S. Sozio et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

A Role for Hypothalamic AMP-Activated Protein Kinase in the Mediation of Hyperphagia and Weight Gain Induced by Chronic Treatment with Olanzapine in Female Rats

(2011) Ei Sejima et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

(2011) Katrina Weston-Green et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Regulation of hepatic lipin-1 by ethanol: Role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice

(2011) Ming Hu et al.   HEPATOLOGY

Dopamine D2 Occupancy as a Biomarker for Antipsychotics: Quantifying the Relationship with Efficacy and Extrapyramidal Symptoms

(2010) Rik de Greef et al.   AAPS Journal

Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats

(2010) Katrina Weston-Green et al.   BEHAVIOURAL BRAIN RESEARCH

The M3-muscarinic acetylcholine receptor stimulates glucose uptake in L6 skeletal muscle cells by a CaMKK–AMPK–dependent mechanism

(2010) Jon Merlin et al.   CELLULAR SIGNALLING

The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

(2010) Chih-Chiang Chiu et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

AMPK-Dependent Metabolic Regulation by PPAR Agonists

(2010) Woo Hyung Lee et al.   PPAR Research

AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome

(2009) Bei B. Zhang et al.   Cell Metabolism

Hepatic Muscarinic Acetylcholine Receptors Are Not Critically Involved in Maintaining Glucose Homeostasis in Mice

(2009) Jian H. Li et al.   DIABETES

Sensitivity of the female rat to olanzapine-induced weight gain—Far from the clinic?

(2009) Katrina Weston-Green et al.   SCHIZOPHRENIA RESEARCH

Cevimeline

(2008) Juliane Weber et al.   DRUGS

Fatty acid metabolism: target for metabolic syndrome

(2008) Salih J. Wakil et al.   JOURNAL OF LIPID RESEARCH

Activation of muscarinic M-3 receptor may decrease glucose uptake and lipolysis in adipose tissue of rats

(2008) Ting-Ting Yang et al.   NEUROSCIENCE LETTERS

Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression

(2008) Mei Han et al.   PSYCHONEUROENDOCRINOLOGY

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL